Fujimoto, N., Miyamoto, Y., Wada, S., Hotta, K., Kozuki, T., Aoe, K., . . . Harada, D. (2021). JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. BMJ Publishing Group.
Style de citation Chicago (17e éd.)Fujimoto, Nobukazu, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, et Daijiro Harada. JME-001 Phase II Trial of First-line Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma. BMJ Publishing Group, 2021.
Style de citation MLA (8e éd.)Fujimoto, Nobukazu, et al. JME-001 Phase II Trial of First-line Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma. BMJ Publishing Group, 2021.